# A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

> **NCT05487391** · PHASE3 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 632 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** QL1706 injection
- **DRUG:** Vinorelbine Tartrate
- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05487391
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-08
- **Primary completion:** 2027-08-31
- **Final completion:** 2029-05-22
- **Target enrollment:** 632 (ESTIMATED)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05487391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05487391, "A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05487391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*